RxDoctor Payments Data

Robert Gunnell, MD

Geriatric Medicine · Grant, MINPI 1225066079

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 32 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 10 manufacturers, the largest accounting for just 16.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $338 and has fallen 63.5% since, to $124 in 2023.

$563in general payments, 2019–2025

Across 32 payments — averaging $17.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$92
  • Otsuka America Pharmaceutical, Inc.$88
  • Vanda Pharmaceuticals Inc.$85
  • Johnson & Johnson$69
  • Alkermes, Inc.$66
  • Indivior Inc.$58
  • plus $105 from 4 others

What the payments were for

  • Food & beverage$563100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$563 in reported general payments places this provider in the 80th percentile of 168 geriatric medicine providers in Michigan.

See all geriatric medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$43,997
Medicare patients
35
Services billed
362

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban198$103,055
VraylarCariprazine Hcl25$18,341
MyrbetriqMirabegron24$11,433
XareltoRivaroxaban15$8,844
CreonLipase/Protease/Amylase12$8,781
Spiriva RespimatTiotropium Bromide12$6,561
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog13$6,307
Lantus SolostarInsulin Glargine,hum.Rec.Anlog70$4,127
Metoprolol Succinate120$3,532
Fentanyl23$2,921
Donepezil Hcl113$2,817
Aripiprazole33$2,390
Potassium Chloride43$2,350
Dexamethasone17$1,856
Furosemide267$1,775

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar, Creon$28$27,12237 claims
Johnson & JohnsonXarelto$69$8,84415 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 168 geriatric medicine providers in Michigan.

Other geriatric medicine in Grant

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →